Biases in medication prescribing: The case of second-generation antipsychotics

Journal of Psychiatric Practice

Volumn 16, Issue 1, 2010, Pages 15-21

  Makhinson, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotic medications; Marketing; Prescribing biases; Schizophrenia; Social psychological biases. cognitive psychological biases

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL PRACTICE; COGNITION; DECISION MAKING; EVIDENCE BASED MEDICINE; PRESCRIPTION; QUALITY OF LIFE; REVIEW; SOCIAL PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; COGNITION; DECISION MAKING; EVIDENCE-BASED MEDICINE; HUMANS; INFORMATION DISSEMINATION; PHYSICIAN'S PRACTICE PATTERNS; PREJUDICE; REINFORCEMENT, SOCIAL;

EID: 76849116973     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000367774.11260.e4     Document Type: Review

References (40)

1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564
2. Emsley R, Oosthuizen P. The new and evolving pharmacotherapy of schizophrenia. Psychiatr Clin North Am 2003;26:141-163
3. Aparasu R, Bhatara V. Antipsychotic use and expenditure in the United States. Psychiatr Serv 2006;57:1693.
4. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: A randomized controlled trial. JAMA 2003;290:2693-2702
5. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
6. Jones PB, Barnes TRE, Davies L, et. al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006;63:1079-1087
7. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007;64:633-647
8. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008;193:279-288
9. Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE study. Am J Psychiatry 2007;164:428-436
10. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 2009;373:31-41.
11. Sernyak MJ, Rosenheck RA. Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatr Serv 2008;59: 567-569
12. Cascade EF, Kalali AH, Lieberman J, et al. Use of antipsychotics pre- and post- dissemination of CATIE data. Psychiatry 2007;4:21-23
13. Drake R, Skinner J, Goldman HH. What explains the diffusion of treatments for mental illness? Am J Psychiatry 2008;165:1385-1392
14. Berwick DM. Disseminating innovations in health care. JAMA 2003;289: 1969-1975
15. Kahneman D, Slovic P, Tversky A. Judgment under uncertainty: Heuristics and biases. New York: Cambridge University Press; 1982
16. Aronson E, Wilson TD, Akert AM. Social psychology, 5th edition. Upper Saddle River, NJ: Prentice Hall; 2005.
17. Cosmides L, Tooby J. Better than rational: Evolutionary psychology and the invisible hand. Amer Econ Rev 1994;84:327-332
18. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982;73:4-8.
19. Hemminki E. Review of literature on the factors affecting drug prescribing. Soc Sci Med 1975;9:111-115
20. Cialdini R. Influence: Science and practice. New York: Harper Collins; 1993.
21. Ramchandani D. Fooling others or oneself? A history of therapeutic fads and its current relevance. Psychiatr Q 2007;78:287-293
22. McHugh PR. Witches, multiple personalities, and other psychiatric artifacts. Nat Med 1995;1:110-114
23. Aronson JK. The NSAID roller coaster: More about rofecoxib. Br J Clin Pharmacol 2006;62:257-259
24. Milgram S. Behavioral study of obedience. J Abnorm Soc Psychol 1963;67:371-378
25. Califf RM, Harrington RA, Blazing MA. Premature release of data from clinical trials of ezetimibe. N Engl J Med 2009;361:712-717
26. Williams JW, Ranney L, Morgan LC, et al. How reviews covered the unfolding scientific story of gabapentin for bipolar disorder. Gen Hosp Psychiatry 2009;31:279-287
27. Richmond J, Sowerby P, Colombo M, et al. The effect of familiarization time, retention interval, and context change on adults' performance in the visual paired-comparison task. Dev Psychobiol 2004;44:146-155
28. Shiv B, Carmen Z, Ariely D. Placebo effects of marketing actions: Consumers may get what they pay for. J Mark Res 2005;42:383-393
29. Kahneman D, Tversky A, eds. Choices, values, and frames. New York: Cambridge University Press; 2000.
30. Hoorens V. Self-enhancement and superiority biases in social comparison. In: Stroebe W, Hewstone M, eds. European review of social psychology, volume 4. Chichester, England:Wiley; 1993: 113-138
31. Kamble P, Chen H, Sherer JT, et. al. Use of antipsychotics among elderly nursing home residents with dementia in the US: An analysis of national survey data. Drugs Aging 2009;26:483-492
32. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-1538
33. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Metaanalysis of randomized placebo-controlled trials. JAMA 2005;294:1934-1943
34. Tatsioni A, Bonitsis NG, Ioannidis JPA. Persistence of contradicted claims in the literature. JAMA 2007;298: 2517-2526
35. Nickerson RS. Confirmation bias: A ubiquitous phenomenon in many guises. Rev Gen Psychol 1998;2:175-220.
36. Zajonc RB. Feeling and thinking: Preferences need no inferences. Am Psychol 1980;35:151-175
37. Croskerry P. The importance of cognitive errors in diagnosis and strategies to minimize them. Acad Med 2003; 78:775-780
38. Lee PE, Sykora K, Gill SS, et al. Antipsychotic medications and drug-induced movement disorders other than Parkinsonism: A population-based cohort study in older adults. J Am Geriatr Soc 2005;53:1374-1379
39. Rochon PA, Stukel TA, Sykora K, et. al. Atypical antipsychotics and Parkinsonism. Arch Intern Med 2005;165: 1882-1888
40. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-260